AACE Pharmaceuticals

AACE Pharmaceuticals is a specialty pharmaceutical company dedicated to developing advanced drug delivery technologies, with a specific focus on the oral delivery of peptides and poorly soluble small molecules. The company utilizes the FDA's 505(b)(2) regulatory pathway to create improved versions of existing therapeutics, aiming to enhance patient convenience and clinical outcomes. Their primary research focus includes metabolic and endocrine disorders such as diabetes, obesity, and hypoparathyroidism. AACE leverages proprietary formulation technologies to overcome biological barriers to drug absorption, transforming injectable treatments into oral dosage forms. The company is headquartered in New Jersey and operates as a development-stage biotech.